Clinical trials: Ranibizumab
Wet Age Related Macular Degeneration
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).
- Trial name
- TWEYES (NCT01986907)
- Testing
- ranibizumab
- Where
- 101 sites in Italy
- Volunteers
- 1,049 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
Select Proliferative Proliferative diabetic retinopathy(PDR) patients who are planning to undergo vitrectomy for informed notification. After obtaining informed consent, vitrectomy will be performed.
- Trial name
- NCT05138029
- Testing
- Ranibizumab Injection [Lucentis], Inner limiting membrane stripping, Dexamethasone intravitreal implant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital of Nantong University
Diabetic Retinopathy
ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR
Purpose: To compare panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) and retinal photocoagulation targeted to ischemic retina combined with…
- Trial name
- NCT03904056
- Testing
- ISQ-RP, ETDRS-PRP group
- Volunteers
- 23 people
- Sponsor
- São Paulo State University
Proliferative Diabetic Retinopathy
Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detachment.
- Trial name
- NCT02857491
- Testing
- ranibizumab, pars plana vitrectomy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Age Related Macular Degeneration
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on…
- Trial name
- FVF4193s (NCT01255774)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The New York Eye & Ear Infirmary
Retinal Hemorrhage, Macular Degeneration
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor.
- Trial name
- NCT00538538
- Testing
- vitrectomy with subretinal lucentis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Corewell Health East
Diabetic Macular Edema
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
The aim of this study is to evaluate the one-year visual outcome and prognostic factors after intraocular injections of ranibizumab under pro re nata treatment regimen for the patients with diabetic macular edema (DME).
- Trial name
- IVRDME (NCT03973138)
- Testing
- Ranibizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Central Retinal Vein Occlusion With Macular Edema
Combination of Ranibizumab and Targeted Laser Photocoagulation
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary…
- Trial name
- CoRaLaII (NCT04444492)
- Testing
- Ranibizumab Injection, Laser photocoagulation
- Where
- 12 sites in Austria, Germany
- Volunteers
- 88 people
- Sponsor
- University of Giessen
Neovascular Age-Related Macular Degeneration
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD…
- Trial name
- RAZORBILL (NCT04662944)
- Testing
- brolucizumab, ranibizumab, aflibercept
- Where
- 17 sites in Canada, Germany and 3 more
- Volunteers
- 494 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal…
- Trial name
- NCT01089517
- Testing
- E10030 plus Lucentis, Lucentis
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Ophthotech Corporation
Uveitic Cystoid Macular Edema
Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Uveitic Cystoid Macular Edema (CME) is a major cause of visual loss associated with uveitis. Systemic and/or local corticosteroid therapy and systemic immunosuppression with steroid-sparing agents such as cyclosporine…
- Trial name
- NCT00826618
- Testing
- ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Corneal Neovascularization
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
- Trial name
- NCT00681889
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Reza Dana, MD